CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
QUETIAPINE	PERFORMANC	*USP38–NF33*	5104	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Line 7 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	E TESTS/ *Dissolution <711>/Test 3*							*Instrumental conditions*: Change 10 0mg, to: 100 mg, AND Line 5 of *Tolerances*: Change *For Tablets labeled to contain 100 mg, 200 mg, 300 mg, or 400 mg*: to: *For Tablets labeled to contain 50 mg, 100 mg, 200 mg, 300 mg, or 400 mg*:
PHENYTOIN SODIUM	*USP Reference standards <11>*	*USP37–NF32*	4289	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Line 3 of USP Phenytoin Related Compound A RS: Change $C_{14}H_{15}NO_2$ to: $C_{14}H_{13}NO_2$
SORBITOL	SPECIFIC	*USP37–NF32*	6197	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Line 1 of *pH*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SORBITAN SOLUTION	TESTS							<*791*>: Change 4.0–7.0, in a 14% solution of Sorbitol Sorbitan Solution in carbon dioxide-free water to: 4.0–7.0, in a 14% (w/w) solution of Sorbitol Sorbitan Solution in carbon dioxide-free water
MINERAL OIL	SPECIFIC TESTS/*Readily Carbonizable Substances Test <271>*	*Second Supplement to USP37–NF32*	Online	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Line 1 of *Acceptance criteria*: Change The *Sample* may turn hazy, but it remains colorless, or shows a slight pink or yellow color, and the *Sample* does not become darker than the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution. to: The oil portion of the *Sample* may turn hazy, but it remains colorless or shows a slight pink or yellow color, and the acid portion of the *Sample* does not become darker than the *Standard solution*.
COSYNTROPIN	SPECIFIC TESTS/*UV Absorption Spectrophotometry*	*USP38–NF33*	2958	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Line 1 of *Sample solution*: Change hydrochloride to: hydrochloric acid
AMINOBENZOIC ACID	IMPURITIES/*Organic Impurities*	*USP37–NF32*	1730	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Add the subsection: *Standard stock solution:* 0.25 mg/mL each of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Benzocaine RS and 4-nitrobenzoic acid in methanol AND Line 2 of *Standard solution*: Change in *Mobile phase* to: in *Mobile phase*, from the *Standard stock solution*
ASPARTAME	ASSAY/ *Procedure*	*USP37–NF32*	5857	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Line 3 of *Analysis*: Change crystal violet to: crystal violet TS
RIVASTIGMINE TARTRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP37–NF32*	Online	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Line 2 of USP Rivastigmine Related Compound A RS: Change Di-*p*-toluoyl-D-(+)-tartaric

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acid monohydrate. $C_{20}H_{20}O_9$ 404.37 to: (+)-Di-(*p*-toluoyl)-D-tartaric acid. $C_{20}H_{18}O_8$ 386.35
CLARITHROMYCIN TABLETS	IMPURITIES/*Organic Impurities/ Chromatographic system*	*USP38–NF33*	2850	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Line 1 of *Column*: Change 4.6-mm × 10-cm; 3-µm packing L1 to: 4.6-mm × 10-cm; 3.5-µm packing L1
RIVASTIGMINE TARTRATE CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP37–NF32*	4616	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Line 2 of USP Rivastigmine Related Compound A RS: Change Di-*p*-toluoyl-D-(+)-tartaric acid monohydrate. $C_{20}H_{20}O_9$ 404.37

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: (+)-Di-(*p*-toluoyl)-D-tartaric acid. $C_{20}H_{18}O_8$ 386.35
TREHALOSE	IM PURITIES/*Heavy Metals, Method I <231>*	*USP37–NF32*	6247	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Line 1 of *Monitor preparation*: Change Prepare with 2.5 mL of *Standard Lead Solution*. to: Prepare with 2.0 mL of *Standard Lead Solution*.
BISMUTH SUB CARBONATE	IM PURITIES/*Limit of Lead*	*USP38–NF33*	2449	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Line 1 of *Acceptance criteria*: Change Meets the requirements to: NMT 0.002%
QUETIAPINE FUMARATE	IM PURITIES/*Organic Impurities*	*USP38–NF33*	5102	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Line 2 of *Peak identification solution*: Change USP Quetiapine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Fumarate Related Compound B RS to: USP Quetiapine Related Compound B RS AND Line 3 of *Peak identification solution*: Change USP Quetiapine Fumarate Related Compound G RS to: USP Quetiapine Related Compound G RS
BETAMETHASONE DIPROPIONATE	ASSAY/ *Procedure*	*USP37–NF32*	1961	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Line 2 of *Sample solution*: Change 5.0 mL each of the *Internal*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								standard solution and the *Standard stock solution* to: 5.0 mL each of the *Internal standard solution* and the *Sample stock solution*
PURIFIED BENTONITE	IDENTIFICATION/*A. X-Ray Diffraction <941>*	*USP37–NF32*	5862	27-Mar-2015	1-Apr-2015	*USP39–NF34*	*USP39–NF34*	Line 4 of *Acceptance criteria*: Change from the pattern of *Sample B* is 1.492 and 1.504 Å. to: from the pattern of *Sample B* is between 1.492 and 1.504 Å.
RED CLOVER TABLETS	SPECIFIC TESTS/ *Microbial Enumeration Tests <2021>*	*USP37–NF32*	5526	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 4: Change NLT 10^3 cfu/g. to: NMT 10^3 cfu/g.
ATROPINE SULFATE	ADDITIONAL REQUIREMENT	*USP38–NF33*	2325	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to*	Line 2 of USP Hyoscyamine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	S/*USP Reference Standards <11>*						*USP38–NF33*	Related Compound A RS: Change Norhyoscyamine sulfate; (1*R*,3*r*,5*S*)-8-azabicyclo[3.2.1]oct-3-yl(2*S*)-3-hydroxy-2-phenylpropanoate.$C_{16}H_{21}NO_3$ 275.34 to: Norhyoscyamine sulfate; (1*R*,3*r*,5*S*)-8-Azabicyclo[3.2.1]octan-3-yl (*S*)-3-hydroxy-2-phenylpropanoate sulfate (2:1).$(C_{16}H_{21}NO_3)_2 \cdot H_2SO_4$ 648.77
CHLORDIAZEPOXIDE AND A	ASSAY/ *Procedure*	*USP38–NF33*	2752	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to*	Line 1 of *Buffer*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MITRIPTYLINE HYDROCHLORIDE TABLETS							*USP38–NF33*	0.20 sodium hydroxide to: 0.20 N sodium hydroxide
PAROXETINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP38–NF33*	4765	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Lines 4 and 7 of USP Paroxetine System Suitability Mixture A RS: Change hydrochloride (3*S-trans*) to: hydrochloride (3*S-trans*)
GADOVERSETAMIDE INJECTION	*Relaxivity <761>*	*USP37–NF32*	3121	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Apparatus*: Change Use a mini-NMR spectrometer with suitable sensitivity (see *Apparatus* under *Nuclear Magnetic Resonance <761>*). to: Use an NMR

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								spectrometer with suitable sensitivity.
BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official October 01, 2014)*	Online	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Row 4 of Column 1 of *Table 16*: Change *R*,*S*,*S*,-Thiomorpholine derivative[c] to: *S*,*R*,*R*,-Thiomorpholine derivative[c]
PANCURONIUM BROMIDE	ASSAY/*Procedure*/*Chromatographic system*	*USP37–NF32*	4176	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Column*: Change 4.6-mm × 250-cm; 5-µm packing L1 to: 4.6-mm × 25-cm; 5-µm packing L1
VALSARTAN TABLETS	PERFORMANCE TESTS/*Dissolution <711>*	*USP37–NF32*	5116	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Medium*: Change pH 6.8 phosphate buffer; 1000 mL, degassed

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: pH 6.8 phosphate buffer prepared as follows. Dissolve 6.805 g of monobasic potassium phosphate and 0.896 g of sodium hydroxide in and dilute with water to 1000 mL. Adjust with 0.2 M sodium hydroxide or 1 M phosphoric acid as required to a pH of 6.8; 1000 mL degassed.
RISPERIDONE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP37–NF32*	7240	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 2 of USP Risperidone Related Compound G RS: Change 3-[2-[4-(4-Fluoro-2-hydroxybenzoyl)piperidin-1-yl]ethyl]-2-meth

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								yl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one. $C_{23}H_{28}FN_3O_3$ 413.49 to: 3-[2-[4-(4-Fluoro-2-hydroxybenzoyl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one hydrochloride. $C_{23}H_{28}FN_3O_3 \cdot HCl$ 448.94
CAFFEINE CITRATE INJECTION	ASSAY/ *Procedure*	*USP38–NF33*	2520	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 5 of *Analysis*: Change Result = $(r_U/r_S) \times C_S \times (M_{r1}/M_{r2}) \times 100$ to: Result = $(r_U/r_S) \times C_S \times (M_{r1}/M_{r2})$
MESALAMINE	OTHER COMP	*USP38–NF33*	4270	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second*	Line 5 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RECTAL SUSPENSION	ONE NTS/*Content of Sodium Benzoate (if present)*						*Supplement to USP38–NF33*	*Analysis*: Change Result = $(r_U/r_S) \times C_S \times (10/W) \times 100$ to: Result = $(r_U/r_S) \times C_S \times (10/W)$
CHLORAMPHENICOL SODIUM SUCCINATE	*Limit of free chloramphenicol*	*USP37–NF32*	2285	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 10 of *Chromatographic system*: Change Chromatograph the *Standard solution*, and record the peak areas as directed for *Procedure*: the relative standard deviation for replicate injections is not less than 2.0%. to: Chromatograph the *Standard solution*, and record the peak areas as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								directed for *Procedure*: the relative standard deviation for replicate injections is not more than 2.0%.
CIPROFLOXACIN EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official October 01, 2014)*	Online	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 13 of *Analysis* in *Test 1*: Change M_{r2} = molecular weight of ciprofloxacin hydrochloride, 367.81 to: M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81 AND Line 12 of *Analysis* in *Test 2*: Change M_{r2} = molecular weight of ciprofloxacin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydrochloride, 367.81 to: M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81 AND Line 13 of *Analysis* in *Test 3*: Change M_{r2} = molecular weight of ciprofloxacin hydrochloride, 367.81 to: M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81
METHOTREXATE	IMPURITIES/*Organic Impurities/Procedure 1: Related*	*USP37–NF32*	3762	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Standard solution A*: Change 0.1 ?g/mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Compounds							USP Methotrexate RS in *Solution A*, from the *Standard stock solution* to: 0.1 µg/mL of USP Methotrexate RS in *Solution A*, from *Standard stock solution A*
TERAZOSIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP37–NF32*	4874	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 10 of *Analysis*: Change M_{r2} = molecular weight of terazosin hydrochloride dihydrate, 459.92 to: M_{r2} = molecular weight of terazosin hydrochloride, 423.89
EXTENDED PHENYTOIN	IDENTIFICATION/*A. Infrared Ab*	*First Supplement to*	6681	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to*	Line 1 of *Sample*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM CAPSULES	*sorption—General <197>*	*USP37–NF32*					*USP38–NF33*	Change 6 mg/mL of phenytoin sodium in water from a suitable number of Capsules prepared as follows. Nominally transfer 300 mg of the powder into 50 mL of water in a separator. to: 300 mg of phenytoin sodium from the contents of Capsules in 50 mL of water in a separator.
BUTABARBITAL SODIUM ORAL SOLUTION	ASSAY/ *Procedure*	*USP38–NF33*	2500	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 17 of *Analysis*: Change C_U = nominal concentration of butabarbital sodium in the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(µg/mL) to: C_U = nominal concentration of butabarbital sodium in the *Sample solution* (mg/mL)
CITRIC ACID, MAGNESIUM OXIDE, AND SODIUM CARBONATE IRRIGATION	ASSAY/*Citric Acid*	*USP38–NF33*	2844	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 16 of *Analysis*: Change C_U = nominal concentration of citric acid monohydrate in the *Assay preparation for citric acid/citrate assay* (units/mL) to: C_U = nominal concentration of citric acid monohydrate in the *Assay preparation for citric acid/citrate assay* (µg/mL)
AZITHROMYCIN	IMPUR	*USP37–NF32*	1886	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to*	Line 6 of *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ITIES/*Organic Impurities/Procedure 1*						*USP38–NF33*	Change Calculate the percentages of desosaminylazithromycin and *N*-demethylazithromycin in the portion of Azithromycin taken: to: Calculate the percentages of desosaminylazithromycin, *N*-demethylazithromycin, and azaerythromycin A in the portion of Azithromycin taken:
VALSARTAN AND HYDROCHLOROTHIAZIDE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Revision Bulletin (Official April 01, 2014)*	Online	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 2 of USP Valsartan Related Compound B RS: Change (*S*-*N*-Butyryl-*N*-([2?-(1*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-tetrazole-5-yl)biphen-4-yl]methyl)-valine. to: *N* -Butyryl -*N* -{[2?-(1*H* -tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine.
HYDROGEN PEROXIDE CONCENTRATE	ASSAY/ *Procedure*	*USP37–NF32*	3272	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Sample solution*: Change 1 mL of Concentrate, diluted to 100 mL to: Weigh about 1 mL of Concentrate in a 100-mL volumetric flask, and dilute with water to volume.
POTASSIUM BITARTRATE	IDENTIFICATION	*USP37–NF32*	4346	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Change *C. Identification Tests—General,*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Tartrate <191> to: *C. Identification Tests—General, Tartrate <191>*: Meets the requirements AND Delete subsections: *Sample solution*: 1 in 10 solution *Acceptance criteria*: Meets the requirements
ZIPRASIDONE HYDROCHLORIDE	IM PURITIES/*Limit of Tetrahydrofuran*	*USP37–NF32*	5219	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Standard solution*: Change 0.05 mg/mL of USP Ziprasidone Hydrochloride RS in dimethyl sulfoxide to: 0.05 mg/mL of tetrahydrofuran in dimethyl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sulfoxide
AMIODARONE HYDROCHLORIDE	ORGANIC IMPURITIES/ *Procedure 1*/ *Chromatographic system*	*USP38–NF33*	2198	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Adsorbent*: Change 0.5-mm layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm to: Suitable layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm
CAFFEINE CITRATE ORAL SOLUTION	ASSAY/ *Procedure*	*USP38–NF33*	2521	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 5 of *Analysis*: Change Result = $(r_U/r_S) \times C_S \times (M_{r1}/M_{r2}) \times 100$ to: Result = $(r_U/r_S) \times C_S \times (M_{r1}/M_{r2})$
PAROXETINE	IM	*USP38–NF33*	4765	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE	PURITIES/*Limit of 1-Methyl-4-(p-fluorophenyl)-1,2,3,6-tetrahydropyridine*						*Supplement to USP38–NF33*	*Standard solution*: Change 42 mg/mL to: 42 ng/mL
ESTRADIOL VAGINAL INSERTS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP37–NF32*	2866	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 3 of *Analysis*: Change Calculate the amount of estradiol ($C_{18}H_{24}O_2$) dissolved: to: Record the chromatograms, and measure the responses for the estradiol peak. Construct a calibration curve by plotting the peak response versus concentration of the *Standard solutions*. Determine the amount of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								estradiol ($C_{18}H_{24}O_2$) in the *Sample solutions* from a linear regression analysis of the calibration curve. Calculate the amount of estradiol ($C_{18}H_{24}O_2$) dissolved: Line 16 of *Analysis*: Change M_{r2} = molecular weight of ciprofloxacin hydrochloride, 367.81 to: M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81 AND Line 14 of the
CIPROFLOXACIN EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official October 01, 2014)*	Online	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								second Calculate statement in *Analysis*: Change M_{r2} = molecular weight of ciprofloxacin hydrochloride, 367.81 to: M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81
PACLITAXEL	*Related compounds/Test 2 (for Material Labeled as Produced by a Semisynthetic Process)*	*USP37–NF32*	4163	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 6 after table in *Chromatographic system*: Change the relative standard deviation for replicate injections is not more than 2.0%. to: the relative

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								standard deviation for replicate injections is not more than 2.0% for the paclitaxel peak.
TETRACAINE OINTMENT	*Assay*	*USP37–NF32*	4891	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 7 of *Procedure*: Change (264.37/300.83)(*C*)(A_U / A_S) to: (264.36/300.82)(*C*)(A_U / A_S)
GLYCERYL BEHENATE	ASSAY/ *Procedure/ Chromatographic system*	*Second Supplement to USP37–NF32*	7075	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Column*: Change 7.0-mm × 60-cm; 5-µm packing L21 [Note—Two 7.0-mm × 30-cm L21 columns to: 7.5-mm × 60-cm; 5-µm 100-Å packing L21 [Note—Two

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								7.5-mm × 30-cm L21 columns
BUTABARBITAL SODIUM TABLETS	PERFORMANCE TESTS/ *Uniformity of Dosage Units <905>/Procedure for content uniformity*	*USP38–NF33*	2501	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 18 of *Analysis*: Change C_U = nominal concentration of butabarbital sodium in the *Sample solution* to: C_U = nominal concentration of butabarbital sodium in the *Sample solution* (mg/mL)
ESCITALOPRAM TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP38–NF33*	3364	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 13 of *Analysis*: Change M_{r2} = molecular weight of escitalopram oxalate, 405.30 to: M_{r2} = molecular weight of escitalopram oxalate, 414.43
AZITHROMYCI	SPECIFIC	*USP37–NF32*	1886	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
N	TESTS/*pH <791>*						*Supplement to USP38–NF33*	*Sample solution*: Change 2 mg/mL from the *Sample stock solution* in a mixture of methanol and water (1:1) to: 2 mg/mL obtained by mixing equal volumes of *Sample stock solution* and water
CIPROFLOXAC IN EXTENDED-RELEASE TABLETS	ASSAY/ *Procedure*	*Revision Bulletin (Official October 01, 2014)*	Online	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 17 of *Analysis*: Change M_{r2} = molecular weight of ciprofloxacin hydrochloride, 367.81 to: M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								367.81

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 17
- Page 18
- Page 19
- Page 20
- Page 21
- Page 22
- Page 23
- Page 24
- Page 25
- …
- Next page Next ›
- Last page Last »